Clínic Barcelona
Clínic Barcelona
Research
May 21 2025
Research news
Clínic Barcelona
Clínic Barcelona
Research
May 20 2025
Fewer than half of clinical trials in mental health report the ethnicity of participants
Clínic Barcelona
Clínic Barcelona
Research
May 19 2025
Allopurinol is designated as the first orphan drug for the treatment of Marfan syndrome
IDIBAPS-Hospital Clínic, the University of Barcelona (UB) and CIBERER are promoting this new advance to fight against a genetic and minority disease1
Clínic Barcelona
Clínic Barcelona
Research
May 16 2025
Study suggests loss of lung capacity begins between the ages of 20 and 25
Research based on eight cohorts from Europe and Australia, provides new guidelines for assessing and monitoring lung health throughout life.
Clínic Barcelona
Clínic Barcelona
Research
May 15 2025
IDIBAPS publishes its Environmental Sustainability Strategy and its Action Plan for the coming years
Clínic Barcelona
Clínic Barcelona
Research
May 14 2025
Researchers decode the brain mechanism that links repeated actions and reward to form stable habits
A study published in the journal Nature and coordinated by the Sainsbury Wellcome Centre in London, with the participation of the IDIBAPS-Hospital Cl1
Clínic Barcelona
Clínic Barcelona
Research
May 14 2025
New tool to enhance the effects of immunotherapy in treating cancer
Clínic Barcelona
Clínic Barcelona
Research
May 13 2025
The ‘Let’s Turn the Page!’ campaign raises €240,000 euros for cancer research through reading
The campaign’s challenge was to collect 12,000 book reviews, and it exceeded its goal. A total of 15,399 reviews were received.
Clínic Barcelona
Clínic Barcelona
Research
May 9 2025
A pioneering study reveals the safety of anaesthetic drugs in patients with Brugada syndrome
A retrospective study conducted at IDIBAPS-Hospital Clínic suggests that many anaesthetic drugs previously considered risky could be safe in patients1
Clínic Barcelona
Clínic Barcelona
Research
May 5 2025
The IDIBAPS Functional Genomics platform incorporates a new automated cell counter
The new Cellometer™ Ascend™ (Revvity) device is a counter that is characterised, among other features, by an automated analysis that provides informa1